Main Points:
– The production processes for T-cell based therapies can be challenging to scale-up.
– Adoption of automated platforms earlier in the process can facilitate scaling up.
– Automating processes can save time in the long run on the path to commercialization.
Author’s Take:
Adopting automation in the production of T-cell based therapies early on can address the scale-up challenges in the sector, potentially saving time and streamlining the path to commercialization. This proactive approach emphasizes the importance of leveraging technology to overcome obstacles and drive efficiency in the biotechnology industry.
Click here for the original article.